drug · antibody
visugromab
Phase 2updated 3mo agoby Catalym GmbH🔗 ChEMBL
Phase 2community read0 votes
Antibody drug with a maximum clinical stage of Phase 2 3, with 1 investigational indication.
all catalysts(0)
nothing on the calendar yet
Trials studying visugromab
- phase3Visugromab in Cachexia International Trial
- phase2Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
- phase2Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- phase2Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
- phase2First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
- phase2Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that